... hand, people whose cancer returned more than one year after treatment or those who were still responding to treatment (known as late relapse) didn’t reach a median overall survival after 10 years. ...
... For those whose doctors recommend postponement, the delay in this important treatment procedure adds to MyMyelomaTeam members’ anxiety and worries. One member whose stem cell transplant was postponed said, “I know I should be grateful for this time, but I am anxious to have the SCT and move forward in my treatment.” “I totally understand! ...
People With Myeloma Face Stress Due to Delayed Treatments
... For those whose doctors recommend postponement, the delay in this important treatment procedure adds to MyMyelomaTeam members’ anxiety and worries. One member whose stem cell transplant was postponed said, “I know I should be grateful for this time, but I am anxious to have the SCT and move forward in my treatment.” “I totally understand! ...
... A combination of brutal honesty and humor, Marrow Me is a must-read for all those whose lives are touched by myeloma.4. ...
... One key measure is called overall response rate (ORR), which is the percentage of people whose cancer shows a partial or total response to treatment.Although there’s no cure for myeloma, BiTEs have shown promise in improving treatment outcomes and extending life expectancy with RRMM. ...
... P-BCMA-ALLO1 is being studied for adults whose myeloma has relapsed or stopped responding to previous treatment. Early results suggest that this CAR T-cell therapy is likely safe and effective. ...
What Is BCMA-Targeted Immunotherapy? (VIDEO)
... P-BCMA-ALLO1 is being studied for adults whose myeloma has relapsed or stopped responding to previous treatment. Early results suggest that this CAR T-cell therapy is likely safe and effective. ...
... This medication has shown benefit in those whose myeloma has returned after several treatments, but it can cause unpleasant eye-related side effects, so regular eye exams are necessary during treatment. ...
... In a statement, the FDA said Spravato should be used in conjunction with an antidepressant pill and is meant only for people whose depression has not responded to at least two other antidepressants. Spravato -- a much less potent relative of the illicit club drug "Special K" -- comes with other restrictions, the FDA said. ...
FDA Approves Ketamine-Like Drug for Severe Depression
... In a statement, the FDA said Spravato should be used in conjunction with an antidepressant pill and is meant only for people whose depression has not responded to at least two other antidepressants. Spravato -- a much less potent relative of the illicit club drug "Special K" -- comes with other restrictions, the FDA said. ...
... Although your oncologist (cancer doctor) and other health care specialists will be the drivers of your myeloma treatment decisions, consider yourself an active passenger whose voice matters. This article is informed by panel discussions at the 2024 Pharma USA conference and summarizes ways you can better advocate for your health care. ...
6 Self-Advocacy Tips From Your Myeloma Doctor
... Although your oncologist (cancer doctor) and other health care specialists will be the drivers of your myeloma treatment decisions, consider yourself an active passenger whose voice matters. This article is informed by panel discussions at the 2024 Pharma USA conference and summarizes ways you can better advocate for your health care. ...
... Around 79.5 percent of people diagnosed with localized myeloma live for at least five years after diagnosis, according to the National Cancer Institute.For people whose myeloma has spread to distant sites beyond where it first developed, the five-year relative survival rate is 59 percent. ...
Multiple Myeloma Prognosis: Survival Rates, Light Chain, and More Factors
... Around 79.5 percent of people diagnosed with localized myeloma live for at least five years after diagnosis, according to the National Cancer Institute.For people whose myeloma has spread to distant sites beyond where it first developed, the five-year relative survival rate is 59 percent. ...
... The CAR T-cell therapy ciltacabtagene autoleucel reduced the risk of death by 45 percent in people whose multiple myeloma had stopped responding to lenalidomide and at least one other treatment. ...
Join
Your Privacy Choices
